Literature DB >> 24356811

Once-daily simeprevir in combination with pegylated-interferon and ribavirin: a new horizon in the era of direct-acting antiviral agent therapy for chronic hepatitis C.

Shinya Maekawa1, Nobuyuki Enomoto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24356811     DOI： 10.1007/s00535-013-0926-7

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN： 0944-1174            Impact factor:   7.527


× No keyword cloud information.
  8 in total

1.  In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

Authors:  Oliver Lenz; Thierry Verbinnen; Tse-I Lin; Leen Vijgen; Maxwell D Cummings; Jimmy Lindberg; Jan Martin Berke; Pascale Dehertogh; Els Fransen; Annick Scholliers; Katrien Vermeiren; Tania Ivens; Pierre Raboisson; Michael Edlund; Susan Storm; Lotta Vrang; Herman de Kock; Gregory C Fanning; Kenneth A Simmen
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

Review 2.  Global control of hepatitis C: where challenge meets opportunity.

Authors:  David L Thomas
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

3.  Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.

Authors:  Hiromitsu Kumada; Joji Toyota; Takeshi Okanoue; Kazuaki Chayama; Hirohito Tsubouchi; Norio Hayashi
Journal:  J Hepatol       Date:  2011-08-07       Impact factor: 25.083

4.  Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study.

Authors:  Michael W Fried; Maria Buti; Gregory J Dore; Robert Flisiak; Peter Ferenci; Ira Jacobson; Patrick Marcellin; Michael Manns; Igor Nikitin; Fred Poordad; Morris Sherman; Stefan Zeuzem; Jane Scott; Leen Gilles; Oliver Lenz; Monika Peeters; Vanitha Sekar; Goedele De Smedt; Maria Beumont-Mauviel
Journal:  Hepatology       Date:  2013-10-11       Impact factor: 17.425

5.  Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.

Authors:  Stefan Zeuzem; Thomas Berg; Edward Gane; Peter Ferenci; Graham R Foster; Michael W Fried; Christophe Hezode; Gideon M Hirschfield; Ira Jacobson; Igor Nikitin; Paul J Pockros; Fred Poordad; Jane Scott; Oliver Lenz; Monika Peeters; Vanitha Sekar; Goedele De Smedt; Rekha Sinha; Maria Beumont-Mauviel
Journal:  Gastroenterology       Date:  2013-11-01       Impact factor: 22.682

6.  Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study.

Authors:  Norio Hayashi; Chiharu Seto; Mai Kato; Yuji Komada; Shoichiro Goto
Journal:  J Gastroenterol       Date:  2013-09-05       Impact factor: 7.527

Review 7.  Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines.

Authors:  Kazuaki Chayama; C Nelson Hayes; Waka Ohishi; Yoshiiku Kawakami
Journal:  J Gastroenterol       Date:  2012-11-28       Impact factor: 7.527

Review 8.  Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region.

Authors:  Mi Na Kim; Beom Kyung Kim; Kwang-Hyub Han
Journal:  J Gastroenterol       Date:  2013-03-06       Impact factor: 7.527
  8 in total
  4 in total

1.  Structure-activity relationship studies on quinoxalin-2(1H)-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870.

Authors:  Qi-Fei Zhong; Rui Liu; Gang Liu
Journal:  Mol Divers       Date:  2015-07-24       Impact factor: 2.943

Review 2.  New treatments for genotype 1 chronic hepatitis C - focus on simeprevir.

Authors:  Tatsuo Kanda; Shingo Nakamoto; Shuang Wu; Osamu Yokosuka
Journal:  Ther Clin Risk Manag       Date:  2014-05-24       Impact factor: 2.423

Review 3.  Simeprevir for the treatment of hepatitis C virus infection.

Authors:  Laure Izquierdo; François Helle; Catherine François; Sandrine Castelain; Gilles Duverlie; Etienne Brochot
Journal:  Pharmgenomics Pers Med       Date:  2014-08-14

4.  Simeprevir and Sofosbuvir Combination Treatment in a Patient with HCV Cirrhosis and HbS Beta 0-Thalassemia: Efficacy and Safety despite Baseline Hyperbilirubinemia.

Authors:  Nikolaos Papadopoulos; Melanie Deutsch; Athanasios Georgalas; Helias Poulakidas; Lazaros Karnesis
Journal:  Case Rep Hematol       Date:  2016-03-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.